GLAND — Gland Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for Gland Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	16,186	10,546	11,325	10,627	14,646
Depreciation
Non-Cash Items	-1,385	-1,085	-1,210	-1,659	-1,469
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-7,996	-7,288	-3,593	-3,599	-7,099
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	7,908	3,640	9,968	9,147	10,314
Capital Expenditures	-5,221	-2,231	-3,983	-3,942	-4,944
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-4,805	14,313	-13,587	20,989	6,322
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-10,026	12,082	-17,569	17,047	1,377
Financing Cash Flow Items	-34	-62.9	-256	-306	-324
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	349	149	-7,994	-4,335	-4,170
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-1,736	15,901	-15,518	21,991	8,029